Safety profile of brentuximab vedotin in Japanese patients with relapsed/refractory Hodgkin lymphoma or systemic anaplastic large cell lymphoma: a post-marketing surveillance study

Brentuximab vedotin (BV) was initially approved in Japan for the treatment of relapsed/refractory (R/R) CD30-positive Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL). As requested by the Japanese Ministry of Health, Labour and Welfare, we conducted a post-marketing surveill...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Int J Hematol
Hlavní autoři: Izutsu, Koji, Ogura, Michinori, Tobinai, Kensei, Hatake, Kiyohiko, Sakamoto, Shigeru, Nishimura, Masanori, Hoshino, Miyako
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer Singapore 2021
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7779085/
https://ncbi.nlm.nih.gov/pubmed/33392974
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12185-020-03039-w
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky